Pharmacokinetic & Activity Levels Achieved with Daily Subcutaneously Administered CB 2679d/ISU304 in Hemophilia B Dogs

H Levy, T Nichols, E Merricks, R Raymer, A Hetherington

OC 10.3 Future Biotherapeutics for Hemophilia A & B
ISTH XXVI Berlin, Germany
10 July 2017
Disclosure

• Employee of Catalyst Biosciences
Factor IX Modified with 3 Point Mutations

- Rapid clearance of FIX necessitates frequent intravenous administrations to achieve effective prophylaxis
- Subcutaneous administration is the preferred route of administration but has been limited by low bioavailability and potency of the marketed FIX products
- Designed as best-in-class high potency recombinant FIX product
- Significantly more potent than currently available products
- Orphan Drug Designation in EU
- Open label, Phase 1/2 proof-of-concept trial underway in individuals with hemophilia B

Factor IX: CB 2679d/ISU304

- R318Y
- R338E
- T343R
CB 2679d/ISU304 Potency Advantage over wt-FIX

- Pro-coagulant Activity: 2.8x
- Affinity for FVIIIa: 10x
- Resistance to ATIII: 15x
- aPTT reduction: 17x
- Tail Clip Model: 20x
- Duration of aPTT Activity: 8x

In-Vitro Assays
In-Vivo activity
Aims & Methods

• Determine pharmacokinetics of daily subcutaneous CB 2679d
• CB 2679d 300 IU/kg was injected SQ daily for 6 days in hemophilia B dogs
• Sampled at 0, 6, 24, 30, 48, 54, 72, 78, 96, 102, 120, 126, 144, 168, 176, 192, 200, 219, 240, 248, 264, 272, 288, 312, 336 and 360 hours
• rhFIX antigen in canine plasma was determined by ELISA using an Affinity Biologicals kit
• FIX activity was measured in duplicate, using a single-stage aPTT-based FIX clotting assay performed on an ACL-TOP instrument using Instrumentation Laboratories reagents
Progressive Increase in Peak and Trough FIX Antigen Levels with Daily Subcutaneous Dosing in Hemophilia B Dogs
FIX Activity is in the Normal Range after 6 Daily Subcutaneous Doses in Hemophilia B Dogs
Rapid & Sustained Correction of Whole Blood Clotting Time in Hemophilia B Dogs with Daily Subcutaneous Dosing

*Levy et al. EAHAD 2017 Haemophilia (2017), 23 (Suppl. 2), 29-140
Results

- Stable normal factor IX blood levels achieved with subcutaneous dosing
  - Daily SQ dosing of CB 2679d after 6 doses had peak FIX activity levels of 60% and 53% at 126 hours
  - Trough activity levels 24 hours after 6th daily dose were 56% and 40% respectively
- No emergent clinical adverse events or laboratory test abnormalities
- No skin reactions recorded
Dog Results Facilitated Ongoing Phase 1/2 Trial

- ISU Abxis is executing the Phase 1/2 trial
- Cohort 1 has been completed
Subcutaneous Dosing May Provide Superior Prophylaxis vs. Extended Half-life Agents

Time in Mild to Normal Levels Predicts Protection from Spontaneous Bleeds

Illustrative Clotting Agent Activity Level

- Normal Clotting Levels
- Mild Hemophilia
- Moderate Hemophilia
- Severe Hemophilia

- SQ Dose Upper Model
- SQ Dose Low Model
- IV Agent

Time after Dosing

- △ SQ Subcutaneous Drug Administration
- ▲ IV Drug Administration
CB 2679d/ISU304 Program Conclusions

• CB 2679d is designed as best-in-class high potency recombinant Factor IX product
• Potency advantage allows subcutaneous administration
• Hemophilia B dogs had daily subcutaneous dosing for 6 days
• Stable normal trough factor IX blood levels achieved after 6 daily subcutaneous doses
• Phase 1/2 subcutaneous trial is ongoing
  – Cohort 1 has been completed
  – Cohort 2 in screening
• Subcutaneous dosing may provide superior prophylaxis to intravenous extended half-life agents
• Orphan drug designation has been granted in EU